Orion - Company Announcement

Composition of R&D Committee as of 15 June 2010

ORION CORPORATION      STOCK EXCHANGE RELEASE  15 June  2010  AT 01.55 EET




The Board of Directors of Orion Corporation has decided to complement the
composition of the R&D Committee with Matti Kavetvuo and Heikki Westerlund as
new members as of 15 June 2010.  Accordingly, all members of the Board of
Directors belong to the R&D Committee.



Composition of the R&D Committee as of 15 June 2010:



Sirpa Jalkanen (Chairman)

Eero Karvonen

Matti Kavetvuo

Hannu Syrjänen

Heikki Westerlund

Jukka Ylppö





Orion Corporation





Timo Lappalainen            Olli Huotari

President and CEO         SVP, Corporate Functions





Contact person:

Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054



Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi <http://www.orion.fi/>





Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler(®)
pulmonary drugs.



The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



[HUG#1424015]